

Study shows seladelpar beneficial for patients with primary biliary cholangitis

February 27 2024, by Elana Gotkine



For patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPAR δ) agonist seladelpar have a biochemical response and alkaline phosphatase normalization, according to a study [published](#) online Feb. 21 in the *New England Journal of Medicine*.

Gideon M. Hirschfield, Ph.D., from the University Health Network in Toronto, and colleagues conducted a [phase 3](#), 12-month, double-blind placebo-controlled trial involving [patients](#) with primary biliary cholangitis with inadequate response to or who had a history of unacceptable side effects with ursodeoxycholic acid. One hundred ninety-three patients were randomly assigned to receive oral seladelpar at a dose of 10 mg daily or placebo in a 2:1 ratio. The primary end point was a biochemical response.

The researchers found that the percentage of patients with a biochemical response was higher in the seladelpar group versus the [placebo group](#) (61.7 versus 20.0%). In addition, significantly more patients who received seladelpar had normalization of the alkaline phosphatase level (25.0 versus 0%). Compared with placebo, seladelpar resulted in a greater reduction in the score on the pruritus numerical rating scale (least-squares mean change from baseline, -3.2 versus -1.7). Overall, 86.7 and 84.6% of patients in the seladelpar and placebo groups, respectively, had adverse events; for serious adverse events, the corresponding values were 7.0 and 6.2%.

"The selective PPAR δ agonist seladelpar elicited biochemical responses while also reducing pruritus in patients with primary biliary cholangitis who had had an inadequate response to or who had a history of unacceptable side effects with ursodeoxycholic acid," the authors write.

More information: Gideon M. Hirschfield et al, A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis, *New England Journal of Medicine* (2024). [DOI: 10.1056/NEJMoa2312100](https://doi.org/10.1056/NEJMoa2312100)

David N. Assis, Advancing Second-Line Treatment for Primary Biliary Cholangitis, *New England Journal of Medicine* (2024). [DOI: 10.1056/NEJMe2312745](https://doi.org/10.1056/NEJMe2312745)

Bernd Schnabl et al, PPAR Agonists in Primary Biliary Cholangitis, *New England Journal of Medicine* (2024). [DOI: 10.1056/NEJMe2313802](https://doi.org/10.1056/NEJMe2313802)

Copyright © 2024 [HealthDay](#). All rights reserved.

Citation: Study shows seladelpar beneficial for patients with primary biliary cholangitis (2024, February 27) retrieved 11 May 2024 from <https://medicalxpress.com/news/2024-02-seladelpar-beneficial-patients-primary-biliary.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--